Neuroleptic malignant syndrome (NMS) is a rare neurological condition associated with the use of antipsychotic medications. Autonomic dysfunction, or damage to the nerves that control involuntary ...

NEW YORK--(BUSINESS WIRE)--NMS Capital (“NMS”) announced today that it has partnered with Company management in the recapitalization of DirectMed Parts & Service, LLC (“DirectMed” or the “Company”).

The US Securities and Exchange Commission (SEC) adopted amendments to Regulation National Market System (Regulation NMS or Reg NMS). Regulation NMS was adopted in 2005 to provide a comprehensive ...

Flourish’s network of 24 sites and 150 investigators conducts studies spanning all phases of clinical trial research Founded in 2010, NMS Capital invests in the lower middle market NMS Capital has ...

Treeways Inc, a portfolio company of NMS Capital, has recapitalized Townville, Pennsylvania-based Hazlett Tree Service Inc, a vegetation management services company. No financial terms were disclosed ...

HORSHAM, Pa.--(BUSINESS WIRE)--NMS Labs announced today that David Delia has been selected as the new President and Chief Executive Officer of the Company. Mr. Delia will guide the organization’s ...

(FLASH FRIDAY is a weekly content series looking at the past, present and future of capital markets trading and technology. FLASH FRIDAY is sponsored by Instinet, a Nomura company.) Is the Reg NMS ...

Neuroleptic malignant syndrome (NMS) is a rare reaction to antipsychotic drugs that are used to treat schizophrenia, bipolar disorder, and other mental health conditions. It affects the nervous system ...